Quotes are at least 15-min delayed:2026/03/12 09:26 EDT
Regular Hours
|
|
|
|
|
||||||||||||
|
|
|
|
|
-- 
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
27.85/11.52
|
|
Enterprise Value
8.63B
|
| Balance Sheet |
|
Book Value Per Share
276.16
|
| Cash Flow |
|
Cash Flow Yield
0.07
|
| Income Statement |
|
Total Revenue
2.58B
|
|
Operating Revenue Per Share
100.79
|
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
